Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Net Margin (2016 - 2025)

Editas Medicine (EDIT) has disclosed Net Margin for 11 consecutive years, with 332.97% as the latest value for Q3 2025.

  • Quarterly Net Margin rose 10152932.0% to 332.97% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 426.12% through Sep 2025, down 8519.0% year-over-year, with the annual reading at 733.71% for FY2024, 53963.0% down from the prior year.
  • Net Margin for Q3 2025 was 332.97% at Editas Medicine, up from 1438.71% in the prior quarter.
  • The five-year high for Net Margin was 31.41% in Q4 2023, with the low at 132683.33% in Q3 2022.
  • Average Net Margin over 5 years is 16318.91%, with a median of 929.25% recorded in 2022.
  • The sharpest move saw Net Margin skyrocketed 13183965bps in 2023, then tumbled -10101861bps in 2024.
  • Over 5 years, Net Margin stood at 14579.16% in 2021, then skyrocketed by 94bps to 929.25% in 2022, then soared by 97bps to 31.41% in 2023, then plummeted by -372bps to 148.32% in 2024, then tumbled by -124bps to 332.97% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 332.97%, 1438.71%, and 1624.37% for Q3 2025, Q2 2025, and Q1 2025 respectively.